Details of the Drug Reposition

General Information of This Drug (ID: DMHTY9W)

Drug Name
Ublituximab   DMHTY9W
Synonyms TG-1101
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple sclerosis DISB2WZI 8A40 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Phase 3 [2]
------------------------------------------------------------------------------------
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Lymphoma DISN6V4S 2A80-2A86 Phase 1/2 [3]
Nodal marginal zone lymphoma DIS7MP4T 2A85.0 Phase 1/2 [3]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761238.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)